NCT07519187招募中1 期
Clinical Study on the Safety and Efficacy of CAR 70-BCMA Dual-Target CAR-T Therapy for Relapsed or Refractory Plasma Cell Neoplasms
The General Hospital of Western Theater Command1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2026年4月23日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 1
研究概览
简要总结
This is a single arm study to evaluate the safety and efficacy of CAR70-BCMA dual-target CAR-T cell therapy for relapsed and refractory plasma cell neoplasms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject or their legally authorized representative has provided written informed consent and is willing and able to comply with scheduled visits, study treatment, laboratory tests, and other study procedures
- •Diagnosis of relapsed or refractory plasma cell neoplasms, defined as follows:
- •Clonal plasma cells positive for BCMA and/or CD70 expression as determined by flow cytometry or immunohistochemistry
- •Patients with multiple myeloma, plasmacytoma, or plasma cell leukemia who have received at least three prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody, and whose best response was less than partial response (PR) or who experienced disease progression after achieving at least PR
- •Patients with systemic light chain amyloidosis who have received at least two prior lines of therapy, including an anti-CD38 monoclonal antibody and either a proteasome inhibitor (PI) or an immunomodulatory agent (IMiD), and whose best response was less than partial response (PR) or who experienced disease progression after achieving at least PR
- •Aged 18 to 75 years (inclusive), male or female
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- •Life expectancy greater than 3 months from the date of informed consent
- •Hemoglobin (HGB) ≥ 60 g/L (transfusion permitted)
- •Adequate hepatic, renal, cardiac, and pulmonary function meeting the following criteria:
- •Creatinine ≤ 2 × upper limit of normal (ULN)
- •Left ventricular ejection fraction (LVEF) ≥ 50%
- •Oxygen saturation > 90%
- •Total bilirubin ≤ 1.5 × ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN
- •The subject agrees to use contraceptive measures from the time of signing the informed consent form until 1 year after CAR-T cell infusion
排除标准
- •Severe cardiac dysfunction with left ventricular ejection fraction (LVEF) < 50%
- •History of severe pulmonary function impairment
- •Concurrent progressive malignancy
- •Concurrent severe infection that cannot be adequately controlled
- •Concurrent severe autoimmune disease or congenital immunodeficiency
- •Active hepatitis, defined as hepatitis B virus deoxyribonucleic acid (HBV-DNA) or hepatitis C virus ribonucleic acid (HCV-RNA) above the lower limit of detection
- •Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection
- •History of severe allergic reaction to biological products (including antibiotics)
- •Patients who have undergone allogeneic hematopoietic stem cell transplantation and still have acute graft-versus-host disease (GVHD) one month after discontinuation of immunosuppressive agents
- •Presence of any other serious physical or mental illness, or laboratory abnormality that may increase the risk of study participation, interfere with the interpretation of study results, or render the patient unsuitable for study enrollment in the opinion of the investigator
- •Female patients of childbearing potential who are pregnant or breastfeeding
研究者
研究点 (1)
Loading locations...
相似试验
招募中
早期 1 期
CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell NeoplasmsNCT07416682Affiliated Hospital to Academy of Military Medical Sciences20
招募中
不适用
To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCTNCT07280494Peking University People's Hospital18
尚未招募
1 期
In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell NeoplasmsNCT07586709Liping Dou18
尚未招募
1 期
Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid LeukemiaNCT07370064Xuzhou Medical University20
招募中
2 期
Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/LeukemiaNCT07321301Daihong Liu10